The Company expects fourth quarter 2025 revenues of $22.5 million to $24.5 million and gross margin in the 58% to 60% range.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HBIO:
- Harvard Bioscience reports Q3 adjusted EPS 0c vs. (2c) last year
- HBIO Upcoming Earnings Report: What to Expect?
- Harvard Bioscience Granted Nasdaq Compliance Extension
- Harvard Bioscience expands distribution agreement with Fisher Scientific
- Harvard Bioscience price target lowered to $2 from $3 at Benchmark